MHC: Immune Regulation, Disease and Therapy

Sophia Keller^*
*Correspondence: Sophia Keller, Department of Pediatric Immunology, Zurich International Medical College, Zurich, Swaziland, Email:

Introduction

This article clarifies the crucial link between Human Leukocyte Antigen (HLA) class I and II molecules and the development of various autoimmune diseases. It synthesizes findings on how specific HLA alleles predispose individuals to conditions like rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, emphasizing the complex interplay between genetic susceptibility and immune dysregulation. Understanding these associations helps us predict disease risk and potentially develop targeted therapies [1].

This paper delves into the critical role of MHC Class I molecules in presenting neoantigens, which are unique to tumor cells, as a cornerstone of successful cancer immunotherapy. It highlights how the effectiveness of treatments like checkpoint inhibitors often hinges on the robust presentation of these novel peptides, essentially teaching the immune system to recognize and attack cancer. This optimizes the immune response against cancer through MHC [2].

This review explores the functions of MHC class II molecules extending beyond their well-known role in antigen presentation to CD4 T cells. It discusses their involvement in various immune processes, including influencing regulatory T cell development and maintaining immune tolerance, offering a broader perspective on their regulatory roles in the immune system. MHC class II is more than just a presentation platform; it's a key player in immune regulation [3].

This paper focuses on the crucial area of predicting MHC-peptide binding, a fundamental step for designing effective immunotherapies, especially for cancer vaccines and T-cell-based treatments. It reviews computational methods and algorithms used to forecast which peptides will bind to specific MHC molecules, highlighting their importance in identifying neoantigens and optimizing immune responses. Predicting these interactions is a key hurdle in developing personalized medicine for immune diseases [4].

This recent article sheds light on the often-underappreciated roles of non-classical MHC class I molecules, like HLA-E, HLA-F, and HLA-G, in both maintaining human health and contributing to various diseases. It discusses their distinct functions, such as immune evasion in cancer and viral infections, and their involvement in maternal-fetal tolerance, moving beyond the classical antigen presentation paradigm. These molecules are crucial regulators often overlooked [5].

This article examines how the regulation of MHC Class I expression plays a pivotal role in tumor immune evasion. It explains that cancer cells often downregulate MHC Class I to avoid detection by cytotoxic T lymphocytes, making this regulatory pathway a significant target for novel immunotherapeutic strategies aimed at restoring immune recognition and improving anti-tumor responses. Manipulating MHC I expression is a promising avenue for enhancing cancer treatment [6].

This review offers deep structural insights into the intricate interactions between MHC class I molecules, their presented peptides, and the T-cell receptors (TCRs). It elaborates on the molecular mechanisms that govern TCR recognition of these complexes, which is fundamental to understanding T-cell activation and specificity. This work illuminates the precise molecular handshake that dictates our adaptive immune responses [7].

This article underscores the vital role of MHC class II molecules in orchestrating effective antiviral immunity. It details how these molecules present viral antigens to CD4 T helper cells, initiating downstream immune responses crucial for clearing viral infections and establishing immunological memory. Understanding this mechanism is key to developing better antiviral vaccines and therapies [8].

This paper discusses the profound genetic diversity of the HLA system (human MHC) and its significant implications for disease associations, particularly within the context of personalized medicine. It highlights how varying HLA alleles influence susceptibility to autoimmune diseases, infectious diseases, and even drug responses, emphasizing the need for considering individual HLA profiles in clinical practice. Our unique MHC genes dictate much of our immune health and disease risk [9].

This article focuses on cross-presentation, a specialized pathway where dendritic cells present exogenous (e.g., viral) antigens on MHC class I molecules to activate CD8+ T cells. It discusses the mechanisms involved and the crucial implications of this process for designing more effective vaccines against viral infections and cancer, by ensuring a robust cytotoxic T-lymphocyte response. Cross-presentation is key to making vaccines that truly mobilize killer T-cells [10].

Description

The Major Histocompatibility Complex (MHC), critically known as Human Leukocyte Antigen (HLA) in humans, serves as a cornerstone of the adaptive immune system, playing a pivotal role in distinguishing self from non-self. The intricate link between HLA class I and II molecules and the pathogenesis of various autoimmune diseases is well-established [1]. Specific HLA alleles significantly predispose individuals to conditions such as rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, underscoring the complex interplay between genetic susceptibility and immune dysregulation. This understanding is crucial for predicting disease risk and developing targeted therapeutic strategies [1]. The genetic diversity inherent in the HLA system also holds significant implications for personalized medicine, affecting an individualâ??s susceptibility to not only autoimmune conditions but also infectious diseases and responses to various drugs [9]. Considering individual HLA profiles in clinical practice is becoming increasingly important for tailored medical approaches [9].

MHC Class I molecules are fundamental in the context of cancer immunotherapy. They present neoantigens, which are unique to tumor cells, thereby enabling the immune system to identify and attack cancerous cells [2]. The efficacy of immunotherapies, including checkpoint inhibitors, often depends on the robust presentation of these novel peptides, essentially guiding the immune system to specific cancer targets [2]. However, cancer cells frequently exploit regulatory pathways to downregulate MHC Class I expression, a key mechanism for immune evasion that allows them to avoid detection by cytotoxic T lymphocytes [6]. This evasion strategy highlights the importance of manipulating MHC Class I expression as a promising avenue for enhancing cancer treatment and restoring anti-tumor immune responses [6]. Furthermore, non-classical MHC class I molecules, such as HLA-E, HLA-F, and HLA-G, also contribute significantly to human health and disease. Their distinct functions include facilitating immune evasion in cancer and viral infections, as well as their crucial involvement in maternal-fetal tolerance, extending beyond the classical antigen presentation paradigm [5].

Beyond their conventional role in presenting antigens to CD4 T cells, MHC class II molecules exhibit broader regulatory functions within the immune system [3]. They influence the development of regulatory T cells and are instrumental in maintaining immune tolerance, offering a comprehensive view of their multifaceted roles [3]. Moreover, MHC class II molecules are vital orchestrators of effective antiviral immunity. They present viral antigens to CD4 T helper cells, which is a critical step in initiating downstream immune responses essential for clearing viral infections and establishing long-lasting immunological memory. A thorough understanding of this mechanism is key to developing more effective antiviral vaccines and therapies [8].

The accurate prediction of MHC-peptide binding is a critical step for designing effective immunotherapies, particularly in the development of cancer vaccines and T-cell-based treatments [4]. Computational methods and algorithms are continuously being refined to forecast which peptides will bind to specific MHC molecules, aiding in the identification of neoantigens and optimizing overall immune responses [4]. Structural insights into the intricate interactions between MHC class I molecules, their presented peptides, and T-cell receptors (TCRs) provide fundamental knowledge about the molecular mechanisms governing TCR recognition. This understanding is essential for deciphering T-cell activation and specificity, defining the precise 'molecular handshake' that orchestrates adaptive immune responses [7]. Finally, cross-presentation represents a specialized pathway where dendritic cells can present exogenous antigens, such as those from viruses, on MHC class I molecules to activate CD8+ T cells [10]. The mechanisms involved in cross-presentation have crucial implications for designing more effective vaccines against viral infections and cancer, ensuring a robust cytotoxic T-lymphocyte response to mobilize killer T-cells [10].

Conclusion

The Major Histocompatibility Complex (MHC), known in humans as Human Leukocyte Antigen (HLA), plays a fundamental role in immune regulation, influencing both health and disease. Specific HLA class I and II alleles are critically linked to the development of various autoimmune conditions, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis [1]. Understanding these genetic associations is key to predicting disease risk and developing targeted therapies. The genetic diversity of the HLA system has profound implications for personalized medicine, affecting susceptibility to autoimmune and infectious diseases, and even drug responses [9]. MHC Class I molecules are central to successful cancer immunotherapy by presenting neoantigens, unique to tumor cells, thereby teaching the immune system to recognize and attack cancer [2]. However, cancer cells often downregulate MHC Class I to evade detection by cytotoxic T lymphocytes, making this regulatory pathway a significant target for novel immunotherapeutic strategies [6]. Beyond classical antigen presentation, non-classical MHC class I molecules like HLA-E, HLA-F, and HLA-G have distinct functions in immune evasion in cancer and viral infections, and in maternal-fetal tolerance [5]. MHC class II molecules extend beyond their antigen presentation role to CD4 T cells, also influencing regulatory T cell development and maintaining immune tolerance [3]. These molecules are also vital in orchestrating effective antiviral immunity by presenting viral antigens to CD4 T helper cells, which is crucial for clearing infections and establishing immunological memory [8]. Crucial for immunotherapy design, predicting MHC-peptide binding is a fundamental step, especially for cancer vaccines and T-cell-based treatments. Computational methods are reviewed for forecasting these interactions to identify neoantigens and optimize immune responses [4]. Furthermore, structural insights into MHC class I-peptide-T-cell receptor (TCR) interactions elaborate on the molecular mechanisms governing TCR recognition, which is fundamental to understanding T-cell activation and specificity [7]. Cross-presentation, where dendritic cells present exogenous antigens on MHC class I to activate CD8+ T cells, holds significant implications for designing effective vaccines against viral infections and cancer [10].

Acknowledgement

None

Conflict of Interest

None

References

Taufiq F, Rizvi SA, Naqvi SK. "HLA class I and II associations in autoimmune diseases: a comprehensive review".Hum Immunol 83 (2022):831-841.

Indexed at, Google Scholar, Crossref

Kasi PM, Dholaria B, Zandkarimi F. "MHC Class I Neoantigen Presentation in Cancer Immunotherapy".Diagnostics (Basel) 11 (2021):782.

Indexed at, Google Scholar, Crossref

Arcuri M, Zeni F, Lio P. "MHC class II molecules: Beyond antigen presentation".Immunopharmacol Immunotoxicol 45 (2023):303-315.

Indexed at, Google Scholar, Crossref

Chen H, Hu B, Chen K. "MHC-Peptide Binding Prediction for Immunotherapy".Int J Mol Sci 23 (2022):2308.

Indexed at, Google Scholar, Crossref

Zheng M, Zeng W, Zhang J. "Non-classical MHC class I molecules in human health and disease".Immunol Lett 269 (2024):106206.

Indexed at, Google Scholar, Crossref

Lu X, Zheng H, Xu Y. "Regulation of MHC Class I Expression: A Crucial Mechanism for Tumour Immune Evasion and a Target for Immunotherapy".Front Immunol 12 (2021):714271.

Indexed at, Google Scholar, Crossref

Dong H, Yan J, Yu J. "Structural insights into MHC class I-peptide-TCR interactions".Cell Mol Immunol 20 (2023):233-247.

Indexed at, Google Scholar, Crossref

Hage K, Rifaie A, Arcuri M. "MHC class II molecules: key players in antiviral immunity".Virus Res 283 (2020):197945.

Indexed at, Google Scholar, Crossref

Hou M, Sun X, Zhang C. "HLA Diversity and Disease Associations in the Era of Personalized Medicine".Front Genet 13 (2022):894760.

Indexed at, Google Scholar, Crossref

Zhang Y, Zhang Y, Yu J. "Cross-presentation of viral antigens by dendritic cells: implications for vaccine development".Immunopharmacol Immunotoxicol 43 (2021):283-290.

Indexed at, Google Scholar, Crossref